Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

, ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

10:55
11/30/16
11/30
10:55
11/30/16
10:55

Arrowhead clinical programs halt seen as boost for small-cap peer Arbutus

Shares of Arrowhead Pharmaceuticals (ARWR) are plunging after the company announced that it is stopping the development of all of its drugs currently being tested on humans due to a setback in the drug-delivery technology. Coming only three weeks after the Food and Drug Administration placed its lead asset for hepatitis B virus on clinical hold, the news sparked several rating downgrades by Wall Street analysts. Additionally, Chardan upgraded Arbutus Biopharma (ABUS) to Buy as the firm views the news as a positive for Arrowhead's competitor. CLINICAL PROGRAMS DISCONTINUED: Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. Both ARC-520 and ARC-521 were aimed at hepatitis B, while ARC-AAT was intended to fight Alpha-1 antitrypsin deficiency, a rare and hereditary illness that can lead to cirrhosis or cancer. Additionally, the company announced that it is reducing its workforce by approximately 30%, while "maintaining full resourcing necessary to support current and potential future partner-based programs and Arrowhead's burgeoning pipeline." ANALYSTS MOVE TO THE SIDELINES: Piper Jaffray analyst Edward Tenthoff downgraded Arrowhead to Neutral from Overweight after the company discontinued its three clinical RNAi candidates, a decision that was based on the FDA clinical hold on ARC-520 due to deaths in an ongoing non-human primate study of high doses of EX1 delivery vehicle. The analyst noted that this was a "negative surprise," and lowered his price target on the shares to $2 from $10. Tenthoff was not the only analyst moving to the sidelines after the program halt announcement. His peer at Cantor also downgraded Arrowhead to Hold from Buy, citing similar reasons. Analyst Elemer Piros told investors in a note of his own that the company is going to focus on its subcutaneously delivered candidates, which are still in early stages of development and lack visibility. He also lowered his price target on the shares to $1 from $15. Meanwhile, William Blair analyst Katherine Xu also downgraded Arrowhead to Market Perform from Outperform, and lowered her price target on the shares to $2 from $12. While the company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, Xu pointed out that she estimates these programs to be at least one to two years away from entering the clinic. HALT POSITIVE FOR COMPETITOR: Research firm Chardan downgraded Arrowhead to Neutral, while upgrading its competitor Arbutus to Buy. Analyst Madhu Kumar told investors that he now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Moreover, the analyst believes that Arrowhead's discontinuations, which are specific to the dynamic polyconjugate platform, should have minimal read-across to Arbutus and its competing assets such as ARB-1467 and ARB-1740, which do not use the same technology. PRICE ACTION: In morning action, shares of Arrowhead have dropped over 64% to $1.57, while Arbutus' stock has gained over 14% to $3.03 per share.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

  • 30

    Nov

  • 06

    Dec

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

11/30/16
WBLR
11/30/16
DOWNGRADE
WBLR
Market Perform
Arrowhead downgraded to Market Perform from Outperform at William Blair
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded on competitor withdrawal at Chardan
As noted earlier, Chardan upgraded Arbutus (ABUS) to Buy from Neutral. Analyst Gbola Amusa upgraded the stock after Arrowhead (ARWR) announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT. The analyst now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Amusa does not expect Arbutus' treatments to cause the same safety problems as those of Arrowhead. Amusa is upbeat on Arbutus' lead asset, ARB-1467. Target to $4 from $3.
11/30/16
11/30/16
DOWNGRADE
Target $2

Market Perform
Arrowhead downgraded at William Blair after clinical programs discontinued
As previously reported, William Blair analyst Katherine Xu downgraded Arrowhead to Market Perform from Outperform after the company announced that it would discontinue all of its current clinical-stage programs three weeks after the FDA placed lead asset ARC-520 for hepatitis B virus on clinical hold. The company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, though Xu estimates these programs are at least one to two years away from entering the clinic. Xu cut her price target on Arrowhead shares to $2 from $12.
11/30/16
11/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABUS Arbutus Biopharma
$2.65

-0.05 (-1.85%)

10/14/16
CHDN
10/14/16
UPGRADE
CHDN
Neutral
Arbutus Biopharma upgraded to Neutral from Sell at Chardan
10/14/16
10/14/16
UPGRADE

Neutral
Arbutus Biopharma upgraded to Neutral on valuation at Chardan
As previously reported, Chardan upgraded Arbutus Biopharma to Neutral from Sell. Analyst MadhuKumar upgraded shares citing relative shares underperformance ahead of Q4 and 2017 clinical catalyst in the Phase IIa study of ARB-1467.
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded to Buy from Neutral at Chardan

TODAY'S FREE FLY STORIES

SBCF

Seacoast Banking

$23.70

-0.53 (-2.19%)

14:33
02/21/17
02/21
14:33
02/21/17
14:33
Conference/Events
Seacoast Banking to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares Trust FTSE/Xinhua China 25 Fund

$38.76

0.3 (0.78%)

14:31
02/21/17
02/21
14:31
02/21/17
14:31
Options
Notable spreads in the Largecap China ETF »

Notable spreads in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$37.35

0.34 (0.92%)

, WCN

Waste Connections

$83.81

0.2099 (0.25%)

14:29
02/21/17
02/21
14:29
02/21/17
14:29
Earnings
Notable companies reporting after market close »

Notable companies…

NEM

Newmont Mining

$37.35

0.34 (0.92%)

WCN

Waste Connections

$83.81

0.2099 (0.25%)

VRSK

Verisk Analytics

$84.90

0.63 (0.75%)

NFX

Newfield Exploration

$42.51

0.69 (1.65%)

KAR

KAR Auction

$46.55

0.07 (0.15%)

XPO

XPO Logistics

$48.60

-0.62 (-1.26%)

FSLR

First Solar

$34.84

0.73 (2.14%)

TXRH

Texas Roadhouse

$48.24

0.13 (0.27%)

TEX

Terex

$32.14

0.14 (0.44%)

PZZA

Papa John's

$86.01

-0.39 (-0.45%)

WLL

Whiting Petroleum

$11.61

0.5 (4.50%)

SPN

Superior Energy

$16.64

0.215 (1.31%)

DEPO

Depomed

$16.47

-0.38 (-2.26%)

RRGB

Red Robin

$47.80

0.05 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

CDE

Coeur Mining

$9.20

0.315 (3.55%)

14:26
02/21/17
02/21
14:26
02/21/17
14:26
Options
Coeur Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
02/21/17
02/21
14:25
02/21/17
14:25
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
02/21/17
02/21
14:25
02/21/17
14:25
Conference/Events
Leerink specialty pharma/biotech analysts hold analyst/industry conference call »

Specialty Pharmaceuticals…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

, TTM

Tata Motors

$34.20

0.74 (2.21%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Volkswagen, Tata Motors in advanced partnership talks, Economic Times says »

Volkswagen (VLKAY) and…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

TTM

Tata Motors

$34.20

0.74 (2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Popeyes declined rival bid from Arby's, Bloomberg reports »

Popeyes Louisiana Kitchen…

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 23

    Mar

14:21
02/21/17
02/21
14:21
02/21/17
14:21
General news
Stocks drifting near all-time best levels »

Stocks remain in positive…

$NSD

NASDAQ Market Internals

14:18
02/21/17
02/21
14:18
02/21/17
14:18
Technical Analysis
NASDAQ Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:17
02/21/17
02/21
14:17
02/21/17
14:17
Technical Analysis
NYSE Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$13.74

0.35 (2.61%)

14:11
02/21/17
02/21
14:11
02/21/17
14:11
Options
Bullish option flow in Pitney Bowes »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

HD

Home Depot

$144.01

1.0148 (0.71%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Upgrade
Exact Sciences rating change  »

Exact Sciences upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AG

First Majestic

$9.86

-0.2 (-1.99%)

14:06
02/21/17
02/21
14:06
02/21/17
14:06
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DVA

DaVita

$68.36

1.46 (2.18%)

, CI

Cigna

$145.74

2.18 (1.52%)

14:02
02/21/17
02/21
14:02
02/21/17
14:02
Hot Stocks
HealthCare Partners, Cigna form alliance to deliver new health plans in L.A. »

HealthCare Partners, a…

DVA

DaVita

$68.36

1.46 (2.18%)

CI

Cigna

$145.74

2.18 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AJG

Arthur J. Gallagher

$56.41

-0.53 (-0.93%)

14:00
02/21/17
02/21
14:00
02/21/17
14:00
Hot Stocks
Arthur J. Gallagher acquires Kelly Financial, terms not disclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

13:55
02/21/17
02/21
13:55
02/21/17
13:55
Recommendations
Exact Sciences analyst commentary  »

Craig-Hallum would still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IMPV

Imperva

$45.70

0.8 (1.78%)

, CHKP

Check Point

$101.21

0.21 (0.21%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Periodicals
Homeland Security having problems with computer systems, Reuters reports »

Some U.S. Department of…

IMPV

Imperva

$45.70

0.8 (1.78%)

CHKP

Check Point

$101.21

0.21 (0.21%)

SYMC

Symantec

$28.80

0.33 (1.16%)

PANW

Palo Alto Networks

$154.58

-0.18 (-0.12%)

QLYS

Qualys

$35.60

1.35 (3.94%)

FFIV

F5 Networks

$143.35

0.11 (0.08%)

FTNT

Fortinet

$37.46

0.215 (0.58%)

CUDA

Barracuda

$23.93

-0.07 (-0.29%)

FEYE

FireEye

$11.83

0.48 (4.23%)

PFPT

Proofpoint

$81.84

0.31 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

K

Kellogg

$74.11

1.21 (1.66%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Options
Hefty call spread in Kellogg as shares rally »

Hefty call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DBD

Diebold

$29.60

-0.5 (-1.66%)

13:47
02/21/17
02/21
13:47
02/21/17
13:47
Conference/Events
Diebold to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MNK

Mallinckrodt

$53.66

-1.0799 (-1.97%)

13:46
02/21/17
02/21
13:46
02/21/17
13:46
Options
Mallinckrodt call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HAS

Hasbro

$98.50

0.86 (0.88%)

13:45
02/21/17
02/21
13:45
02/21/17
13:45
Conference/Events
Hasbro management to meet with Wells Fargo »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

, GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

13:44
02/21/17
02/21
13:44
02/21/17
13:44
Hot Stocks
Korn Ferry Futurestep partners with GlaxoSmithKline over talent acquisition »

Futurestep division of…

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

13:35
02/21/17
02/21
13:35
02/21/17
13:35
General news
NY Fed accepted $163.3 B in daily reverse repos »

NY Fed accepted $163.3 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.